An Open-label Study to Assess the Absorption Through the Mouth After Three Repeated 50 mg Doses of Eliglustat Solution, Separated by 2-hour Intervals, Held in the Mouth for 30 Seconds With Swishing But Without Ingestion, in Healthy Subjects
Latest Information Update: 09 Jan 2024
At a glance
- Drugs Eliglustat (Primary)
- Indications Gaucher's disease
- Focus Pharmacokinetics
- Acronyms Acronym
- Sponsors Sanofi
Most Recent Events
- 09 Jan 2024 New trial record